SG11201809899RA - Method of treating hyperglycemia - Google Patents

Method of treating hyperglycemia

Info

Publication number
SG11201809899RA
SG11201809899RA SG11201809899RA SG11201809899RA SG11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA
Authority
SG
Singapore
Prior art keywords
yuanqu
vpm
dist
taiwan
international
Prior art date
Application number
SG11201809899RA
Other languages
English (en)
Inventor
Jui-Pao Hsu
Guang-Tzuu Shane
Meng-Ju Lee
Yi-Ping Liao
Yu-Yin Yeh
Original Assignee
Center Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center Laboratories Inc filed Critical Center Laboratories Inc
Publication of SG11201809899RA publication Critical patent/SG11201809899RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
SG11201809899RA 2016-05-20 2017-05-17 Method of treating hyperglycemia SG11201809899RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339131P 2016-05-20 2016-05-20
PCT/CN2017/084746 WO2017198177A1 (en) 2016-05-20 2017-05-17 Method of treating hyperglycemia

Publications (1)

Publication Number Publication Date
SG11201809899RA true SG11201809899RA (en) 2018-12-28

Family

ID=60326464

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809899RA SG11201809899RA (en) 2016-05-20 2017-05-17 Method of treating hyperglycemia

Country Status (15)

Country Link
US (2) US9980935B2 (es)
EP (1) EP3413886A4 (es)
JP (3) JP6692903B2 (es)
KR (3) KR20210000757A (es)
CN (2) CN113384571A (es)
AU (1) AU2017267006B2 (es)
BR (1) BR112018073688A2 (es)
CA (2) CA3114057A1 (es)
HK (1) HK1254471A1 (es)
IL (1) IL262994B2 (es)
MX (1) MX2018013943A (es)
RU (2) RU2020140694A (es)
SG (1) SG11201809899RA (es)
TW (1) TWI659738B (es)
WO (1) WO2017198177A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020140694A (ru) * 2016-05-20 2021-01-25 Сентер Лабораториз, Инк. Способ лечения гипергликемии
US10639292B2 (en) 2018-04-20 2020-05-05 Center Laboratories, Inc. Method of treating hyperglycemia
EP3981401A1 (en) * 2020-10-06 2022-04-13 InSphero AG Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic
EP4329756A1 (en) * 2021-04-29 2024-03-06 Ildong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616549D0 (en) * 1996-08-06 1996-09-25 Chiroscience Ltd Therapeutic product and its use
US20030092765A1 (en) * 2001-11-15 2003-05-15 John Kelly Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil
KR101438234B1 (ko) * 2005-06-03 2014-09-04 미쓰비시 타나베 파마 코퍼레이션 의약의 병용 및 그 용도
RU2338521C1 (ru) * 2007-02-28 2008-11-20 Илья Николаевич Медведев Способ быстрого снижения активности тромбопластиногенерации у лиц с метаболическим синдромом
CA2755068C (en) * 2009-03-12 2018-11-06 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
CN101869708A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 含有钙通道阻滞剂和双胍类降糖药物的药物组合物及其用途
JP2012528170A (ja) * 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
TWI410630B (zh) * 2009-11-10 2013-10-01 Ct Lab Inc 一種用以治療與食慾素受體１、食慾素受體２、體抑素受體２或多巴胺ｄ２ｌ受體相關之疾病的方法和組合物
MX2012005425A (es) * 2009-11-13 2012-06-14 Astrazeneca Uk Ltd Formulaciones de metformina de masa reducida.
EP2573088A1 (en) * 2011-09-26 2013-03-27 Prous Institute for Biomedical Research, S.A. Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof
WO2015142865A2 (en) * 2014-03-17 2015-09-24 Massachusetts Institute Of Technology Metakaryocidal treatments
CN107108477A (zh) * 2014-10-29 2017-08-29 晟德大药厂股份有限公司 盐酸维拉帕米结晶型
RU2020140694A (ru) * 2016-05-20 2021-01-25 Сентер Лабораториз, Инк. Способ лечения гипергликемии

Also Published As

Publication number Publication date
US10278943B2 (en) 2019-05-07
KR20210121305A (ko) 2021-10-07
CN108430467A (zh) 2018-08-21
KR20180058816A (ko) 2018-06-01
KR102200664B1 (ko) 2021-01-08
JP2022050572A (ja) 2022-03-30
KR20210000757A (ko) 2021-01-05
BR112018073688A2 (pt) 2019-02-26
US20170333382A1 (en) 2017-11-23
EP3413886A4 (en) 2019-09-18
TWI659738B (zh) 2019-05-21
US20180235921A1 (en) 2018-08-23
RU2020140694A (ru) 2021-01-25
JP2019503983A (ja) 2019-02-14
CN108430467B (zh) 2021-06-22
CN113384571A (zh) 2021-09-14
CA3003319C (en) 2021-05-25
AU2017267006A1 (en) 2018-05-10
JP6692903B2 (ja) 2020-05-13
KR102423967B1 (ko) 2022-07-21
RU2739255C2 (ru) 2020-12-22
JP7266327B2 (ja) 2023-04-28
WO2017198177A1 (en) 2017-11-23
US9980935B2 (en) 2018-05-29
CA3114057A1 (en) 2017-11-23
RU2018139578A (ru) 2020-06-22
CA3003319A1 (en) 2017-11-23
HK1254471A1 (zh) 2019-07-19
MX2018013943A (es) 2019-03-28
EP3413886A1 (en) 2018-12-19
RU2020140694A3 (es) 2021-10-08
JP2020100651A (ja) 2020-07-02
TW201740933A (zh) 2017-12-01
IL262994B2 (en) 2023-07-01
RU2018139578A3 (es) 2020-06-22
AU2017267006B2 (en) 2019-07-11
IL262994B1 (en) 2023-03-01
IL262994A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804915RA (en) Methods for treating huntington's disease
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201809899RA (en) Method of treating hyperglycemia
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase